All In Biotech

Drug Trial Radar · NCT07698600

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

A Randomized, Placebo-controlled, Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity, and Impact on Virological Control of the Investigational RNA-based Vaccine BNT168 in Adults Living With or Without HIV

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.

Conditions

  • HIV -1 Infection

Interventions

  • BNT168Biological

    Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections

  • PlaceboOther

    Isotonic sodium chloride (NaCl) solution (0.9%). Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of at least one adverse eventTime frame: From dosing through 28 days after each IMP dose
  2. Occurrence of at least one serious adverse eventTime frame: From Dose 1 through the end of study (up to 12 months)
  3. Occurrence of at least one adverse event of special interestTime frame: From Dose 1 through the end of study (up to 12 months)
  4. Occurrence of at least one solicited local reaction (pain, erythema/redness, swelling) at the IMP injection siteTime frame: Up to 7 days after each IMP dose
  5. Occurrence of at least one solicited systemic event (vomiting, diarrhea, headache, fatigue/tiredness, myalgia/muscle pain, fever)Time frame: Up to 7 days after each IMP dose

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • AMR Clinical Knoxville

    Knoxville, Tennessee · Recruiting

  • The Crofoot Research Center

    Houston, Texas · Recruiting

  • Perinatal HIV Research Unit (PHRU)

    Johannesburg, South Africa · Recruiting

  • Wits RHI - Shandukani Research

    Johannesburg, South Africa · Recruiting

  • Clinical HIV Research Unit (CHRU)

    Johannesburg, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.